MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, and sale of aortic and peripheral vascular medical devices in China and internationally. The company offers branched aortic, thoracic, and bifurcated stent graft system; abdominal aortic stent graft and delivery system; and other stent graft system in surgical operation; as well as accessorie… Read more
MicroPort Endovascular MedTech Ltd (688016) - Net Assets
Latest net assets as of September 2025: CN¥3.98 Billion CNY
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has net assets worth CN¥3.98 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.73 Billion) and total liabilities (CN¥750.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.98 Billion |
| % of Total Assets | 84.15% |
| Annual Growth Rate | 53.6% |
| 5-Year Change | 209.77% |
| 10-Year Change | N/A |
| Growth Volatility | 123.99 |
MicroPort Endovascular MedTech Ltd - Net Assets Trend (2016–2024)
This chart illustrates how MicroPort Endovascular MedTech Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MicroPort Endovascular MedTech Ltd (2016–2024)
The table below shows the annual net assets of MicroPort Endovascular MedTech Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.82 Billion | -1.06% |
| 2023-12-31 | CN¥3.86 Billion | +121.71% |
| 2022-12-31 | CN¥1.74 Billion | +14.49% |
| 2021-12-31 | CN¥1.52 Billion | +23.35% |
| 2020-12-31 | CN¥1.23 Billion | +15.76% |
| 2019-12-31 | CN¥1.07 Billion | +393.15% |
| 2018-12-31 | CN¥216.16 Million | +14.97% |
| 2017-12-31 | CN¥188.02 Million | +52.39% |
| 2016-12-31 | CN¥123.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MicroPort Endovascular MedTech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 21775.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.08 Billion | 28.61% |
| Common Stock | CN¥123.26 Million | 3.25% |
| Other Comprehensive Income | CN¥-13.71 Million | -0.36% |
| Other Components | CN¥2.60 Billion | 68.50% |
| Total Equity | CN¥3.79 Billion | 100.00% |
MicroPort Endovascular MedTech Ltd Competitors by Market Cap
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hypera S.A
SA:HYPE3
|
$1.04 Billion |
|
Controladora Vuela Compañía de Aviación S.A.B. de C.V
F:2CDA
|
$1.04 Billion |
|
EVN AG
VI:EVN
|
$1.04 Billion |
|
McEwen Mining Inc.
NYSE:MUX
|
$1.04 Billion |
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
$1.04 Billion |
|
Anhui Guangxin Agrochemical Co Ltd
SHG:603599
|
$1.04 Billion |
|
Societatea Nationala de Gaze Naturale Romgaz SA GDR (Sponsored) Reg S
PINK:SLTQY
|
$1.04 Billion |
|
YUEXIU PPTY CO.LTD.
F:GUZA
|
$1.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MicroPort Endovascular MedTech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,843,816,151 to 3,791,843,035, a change of -51,973,116 (-1.4%).
- Net income of 502,100,209 contributed positively to equity growth.
- Dividend payments of 450,460,130 reduced retained earnings.
- Share repurchases of 120,002,258 reduced equity.
- Other comprehensive income decreased equity by 15,299,902.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥502.10 Million | +13.24% |
| Dividends Paid | CN¥450.46 Million | -11.88% |
| Share Repurchases | CN¥120.00 Million | -3.16% |
| Other Comprehensive Income | CN¥-15.30 Million | -0.4% |
| Other Changes | CN¥31.69 Million | +0.84% |
| Total Change | CN¥- | -1.35% |
Book Value vs Market Value Analysis
This analysis compares MicroPort Endovascular MedTech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 46.90x to 3.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥2.29 | CN¥107.25 | x |
| 2017-12-31 | CN¥3.48 | CN¥107.25 | x |
| 2018-12-31 | CN¥4.01 | CN¥107.25 | x |
| 2019-12-31 | CN¥14.81 | CN¥107.25 | x |
| 2020-12-31 | CN¥17.14 | CN¥107.25 | x |
| 2021-12-31 | CN¥20.76 | CN¥107.25 | x |
| 2022-12-31 | CN¥23.88 | CN¥107.25 | x |
| 2023-12-31 | CN¥49.69 | CN¥107.25 | x |
| 2024-12-31 | CN¥30.74 | CN¥107.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MicroPort Endovascular MedTech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.24%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 41.62%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.13x
- Recent ROE (13.24%) is below the historical average (23.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 33.32% | 32.81% | 0.66x | 1.53x | CN¥28.78 Million |
| 2017 | 33.71% | 38.38% | 0.74x | 1.19x | CN¥44.58 Million |
| 2018 | 41.94% | 39.22% | 0.86x | 1.24x | CN¥69.03 Million |
| 2019 | 13.30% | 42.48% | 0.29x | 1.08x | CN¥35.16 Million |
| 2020 | 17.39% | 45.64% | 0.34x | 1.12x | CN¥91.22 Million |
| 2021 | 21.14% | 46.14% | 0.39x | 1.17x | CN¥166.43 Million |
| 2022 | 20.76% | 39.81% | 0.45x | 1.16x | CN¥185.01 Million |
| 2023 | 12.81% | 41.48% | 0.28x | 1.10x | CN¥108.05 Million |
| 2024 | 13.24% | 41.62% | 0.28x | 1.13x | CN¥122.92 Million |
Industry Comparison
This section compares MicroPort Endovascular MedTech Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,121,810,098
- Average return on equity (ROE) among peers: 128.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MicroPort Endovascular MedTech Ltd (688016) | CN¥3.98 Billion | 33.32% | 0.19x | $1.04 Billion |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $1.03 Billion | 22.10% | 0.17x | $320.58 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $6.16 Billion | 12.22% | 0.29x | $2.80 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $405.66 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $21.45K | 1180.66% | 90.26x | $283.55 Million |
| Lepu Medical Tech Beijing (300003) | $7.03 Billion | 12.79% | 0.82x | $2.80 Billion |
| INKON Life Technology Co Ltd (300143) | $74.89 Million | 13.27% | 0.87x | $630.90 Million |
| Edan Instruments Inc (300206) | $152.19 Million | 30.16% | 0.31x | $509.86 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.29 Billion | -5.53% | 0.94x | $378.42 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $269.46 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $952.60 Million |